Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Top Cited Papers
Open Access
- 2 November 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (17) , 1874-1883
- https://doi.org/10.1001/jama.2011.1558
Abstract
Increasing age has been historically implicated in higher mortality after high-dose allogeneic hematopoietic cell transplantation (HCT) for patients with hematologic malignancies.1 Such transplants are preceded by intense, cytotoxic conditioning regimens aimed at reducing tumor burden. The risk of organ toxicities has limited the use of high-dose regimens to younger patients in good medical condition. Therefore, age cutoffs of 55 to 60 years have been in place for decades for high-dose HCT. This excluded the vast majority of patients from allogeneic HCT, given that median ages of patients at diagnoses of most hematologic malignancies range from 65 to 70 years.2,3Keywords
This publication has 32 references indexed in Scilit:
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood, 2010
- Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative ConditioningJournal of Clinical Oncology, 2005
- Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantationLeukemia, 2004
- Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioningExperimental Hematology, 2003
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignanciesBlood, 2003
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsBlood, 2001
- Modelling prevalence of a condition: chronic graft-versus-host disease after bone marrow transplantationStatistics in Medicine, 1997
- 1994 Consensus Conference on Acute GVHD Grading.1995
- Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up.1992